Literature DB >> 22487721

Structural basis for high selectivity of anti-CCL2 neutralizing antibody CNTO 888.

Galina Obmolova1, Alexey Teplyakov, Thomas J Malia, Tami L R Grygiel, Raymond Sweet, Linda A Snyder, Gary L Gilliland.   

Abstract

Human CC chemokine ligand 2 (CCL2), also known as monocyte chemoattractant protein-1 (MCP-1), is a member of the β chemokine family whose actions are mediated through the G-protein-coupled receptor CCR2. Binding of CCL2 to its receptor CCR2 triggers calcium mobilization and chemotaxis. CCL2 is implicated in the pathogenesis of certain inflammatory diseases and cancer. CNTO 888, a neutralizing human anti-CCL2 antibody, was derived by antibody phage display. The antibody binds human CCL2 with high affinity (K(D)=22 pM) and inhibits CCL2 binding to its receptor. The crystal structure of the CNTO 888 Fab alone and in complex with the monomeric form of CCL2 (P8A variant) was determined at 2.6 Å and 2.8 Å resolution, respectively. CNTO 888 recognizes a conformational epitope encompassing residues 18-24 and 45-51 that overlaps the mapped receptor binding site. The epitope of CNTO 888 does not overlap with the dimerization site of CCL2, and thus its inhibitory activity is not expected to result from interference with the oligomeric state of CCL2. Comparison of the X-ray-determined epitopes of CNTO 888 and another CCL2-neutralizing antibody, 11K2, provides insight into the molecular basis of antibody selectivity and functional inhibition.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22487721     DOI: 10.1016/j.molimm.2012.03.022

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  12 in total

1.  Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.

Authors:  Irene Brana; Antonio Calles; Patricia M LoRusso; Lorrin K Yee; Thomas A Puchalski; Shobha Seetharam; Bob Zhong; Carla J de Boer; Josep Tabernero; Emiliano Calvo
Journal:  Target Oncol       Date:  2014-06-15       Impact factor: 4.493

2.  Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers.

Authors:  Francois Moisan; Edgar B Francisco; Anamaria Brozovic; George E Duran; Yan C Wang; Shalini Chaturvedi; Shobha Seetharam; Linda A Snyder; Parul Doshi; Branimir I Sikic
Journal:  Mol Oncol       Date:  2014-04-18       Impact factor: 6.603

3.  Crystal structure of a mirror-image L-RNA aptamer (Spiegelmer) in complex with the natural L-protein target CCL2.

Authors:  Dominik Oberthür; John Achenbach; Azat Gabdulkhakov; Klaus Buchner; Christian Maasch; Sven Falke; Dirk Rehders; Sven Klussmann; Christian Betzel
Journal:  Nat Commun       Date:  2015-04-22       Impact factor: 14.919

Review 4.  Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy.

Authors:  Erika Vacchelli; Fernando Aranda; Alexander Eggermont; Jérôme Galon; Catherine Sautès-Fridman; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-01-01       Impact factor: 8.110

5.  Structures of human CCL18, CCL3, and CCL4 reveal molecular determinants for quaternary structures and sensitivity to insulin-degrading enzyme.

Authors:  Wenguang G Liang; Min Ren; Fan Zhao; Wei-Jen Tang
Journal:  J Mol Biol       Date:  2015-01-28       Impact factor: 5.469

Review 6.  Support of Tumor Endothelial Cells by Chemokine Receptors.

Authors:  Nicole Salazar; Brian A Zabel
Journal:  Front Immunol       Date:  2019-02-08       Impact factor: 7.561

Review 7.  International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.

Authors:  Francoise Bachelerie; Adit Ben-Baruch; Amanda M Burkhardt; Christophe Combadiere; Joshua M Farber; Gerard J Graham; Richard Horuk; Alexander Hovard Sparre-Ulrich; Massimo Locati; Andrew D Luster; Alberto Mantovani; Kouji Matsushima; Philip M Murphy; Robert Nibbs; Hisayuki Nomiyama; Christine A Power; Amanda E I Proudfoot; Mette M Rosenkilde; Antal Rot; Silvano Sozzani; Marcus Thelen; Osamu Yoshie; Albert Zlotnik
Journal:  Pharmacol Rev       Date:  2013-11-11       Impact factor: 25.468

8.  Protein crystallization with microseed matrix screening: application to human germline antibody Fabs.

Authors:  Galina Obmolova; Thomas J Malia; Alexey Teplyakov; Raymond W Sweet; Gary L Gilliland
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2014-07-23       Impact factor: 1.056

9.  Structural diversity in a human antibody germline library.

Authors:  Alexey Teplyakov; Galina Obmolova; Thomas J Malia; Jinquan Luo; Salman Muzammil; Raymond Sweet; Juan Carlos Almagro; Gary L Gilliland
Journal:  MAbs       Date:  2016-05-21       Impact factor: 5.857

Review 10.  Targeting the CCL2-CCR2 signaling axis in cancer metastasis.

Authors:  Su Yin Lim; Arseniy E Yuzhalin; Alex N Gordon-Weeks; Ruth J Muschel
Journal:  Oncotarget       Date:  2016-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.